Compare DexCom, Inc. (DXCM) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs CarMax, Inc — how do they compare? DexCom, Inc. trades at $78.45 (market cap $28.06B), while CarMax, Inc trades at $60.75 (market cap $8.36B). The key difference: DexCom, Inc. is far larger — about 3.4× CarMax, Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | KMX | |
|---|---|---|
Market Cap | $28.06B | $8.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $63.53 |
52-Week Low | $54.84 | $30.88 |
Enterprise Value | $27.03B | $26.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
CarMax (KMX) trades at $55.73, up 1.57% with bullish technical signals from moving averages. The company shows mixed fundamentals with a high P/E of 36.61 but attractive P/S of 0.32, while recent Q1 2026 earnings beat expectations. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, though net income improved to $500.56M. Technical analysis indicates bullish momentum with support at $55 and resistance at $56.
Outlook remains cautious with analyst consensus at Hold (62.86%) and price target of $48.91 below current levels. Key risks include ongoing margin pressure and high debt load of $18.14B. Positive catalysts include the four-pillar turnaround strategy gaining traction and insider buying activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
